Do Business With Optimi

Capitalizing on the strength of our strong leadership team and Canadian-built facilities, Optimi is able to provide full service offerings for organizations in need of our expertise and production capabilities.

Send Us A Message
Or, Schedule a meeting with our business development team and discuss opportunities for collaboration.
Book A Meeting Now.

“Establishing Optimi’s presence in the psychedelic market begins with trust, which we believe we have earned through our in-house expert research and world-class advisory team, and by setting the gold standard in GMP compliance.”

- JJ Wilson, Optimi Co-Founder

Business Advantage...

We are focused on helping our clients address their most significant and complex drug discovery and therapeutic development challenges.

Five Reasons to Do Business With Optimi:

1.

We are one of only 22 licensed dealers approved by Health Canada to produce psilocybin and synthetic psychedelic products.

3.

We specialize in global trade compliance and are fully licensed to package and export our products internationally using our in-house distribution experts.

2.

We specialize in global trade compliance and are fully licensed to package and export our products internationally using our in-house distribution experts.

2.

We have been approved by Health Canada to supply Canada's Special Access Program (SAP) and Clinical Trials.

3.

We have been approved by Health Canada to supply Canada's Special Access Program (SAP) and Clinical Trials.>

4.

We have the largest, EU-GMP psilocybin cultivation facility in the world.

5.

We have one of the largest genetic strain banks of psilocybin and functional mushrooms in the sector.

Business Opportunities

Business Opportunities

Special Access Programs

Optimi produces the purest natural and synthetic pharmaceutical-grade investigational drugs to authorized patients and physicians in Canada under the Special Access Program(SAP).

Our team of medical and business professionals are able to assist patients and physicians with the SAP application process by contacting us at sales@optimihealth.ca.

Download the application here.

Announced on January 5, 2022, the SAP allows qualified medical practitioners to request access to Schedule 3 controlled substances such as psilocybin on a case-by-case emergency basis. Prior to the new regulatory amendments, medical practitioners were prohibited from requesting access to psilocybin and MDMA for individual psychedelic-assisted psychotherapy. The amendments have the potential to positively affect the lives of people experiencing serious mental health conditions and end-of-life distress when other therapies have failed, are unsuitable or are unavailable in Canada.

Optimi is on list of approved Health Canada suppliers and can work with patients and physicians to legally supply psilocybin under the SAP. 

Clinical Trials

Optimi is the only EU-GMP qualified cultivator in Canada with the ability to supply clinical trials with pure biomass and synthetic formulations at scale.

Researchers need access to the purest natural source of psilocybin, and they need it fast.

With hundreds of ongoing and future multi-phase clinical trials studying the effects of psilocybin and other synthetic psychedelics on a variety of health conditions, Optimi is able to meet consumer demand.

We possess one of the largest genetic strain banks of psilocybin in the industry and are happy to provide further consultation on our products.

sales@optimihealth.ca 

Analytics Lab

Optimi Labs has developed an intellectual property (IP) strategy encompassing delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new formulations, testing and protocol regimens specific to mushroom-based products and synthetic psychedelic compounds.

To expedite innovation, Optimi Labs works with both academic and strategic development partnerships led by our Chief Science Officer, Justin Kirkland.

With hundreds of ongoing and future multi-phase clinical trials studying the effects of psilocybin and other synthetic psychedelics on a variety of health conditions, Optimi is able to meet consumer demand.

We possess one of the largest genetic strain banks of psilocybin in the industry and are happy to provide further consultation on our products.

sales@optimihealth.ca 

Our facilities house the latest analytical instrumentation for a full range of testing, including API/Product release, stability and dissolution.

We provide our clients with:

  • Optimized commercial cultivation processes.
  • Optimized strain development, breeding, quality, and overall yields.
  • Proprietary extraction techniques that could yield a fully active transdermal active product.
  • Medicinal mushroom IP strategic initiatives resulting in the ability to treat unmet needs.

Drug Outsourcing

Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market.

In 2021, the lead identification & candidate optimization segment dominated the market. It is one of the most critical processes in drug discovery. Small molecules dominated the market in 2021, and the segment is also projected to register a high CAGR during the forecast period.

The growth can be attributed to the government initiatives to forge alliances with U.S. pharmaceutical companies.

Drug discovery is a costly and lengthy process, which has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). The global drug discovery outsourcing market size is expected to reach USD $6.3 billion by 2030 at a CAGR of 7.4%.

Value Proposition

Regulatory

Per GMP standards, all of the products at Optimi are fully tested and characterized to USP and Health Canada regulations.

Quality

Our Quality team ensures all published and internal standards are met prior to releasing our products for sale.

Controls

We have additional controls in place auditing our supply chain, air and water quality as well as legal compliance.

Extract

Our extract products undergo an additional assay that includes residual solvent testing under USP 467.

Current Partners

We’re ready to talk...

Out team is looking forward to meeting with you and talking about growing our businesses.

FAQs

Health Canada has granted Optimi Health what is known as a Controlled Substances Dealer’s Licence, allowing us to cultivate psilocybin containing mushrooms for sale and export to other authorized parties.

You can read more about Optimi’s regulatory and compliance efforts here.

Optimi Health is the largest producer of GMP psilocybin in North America, and has recently expanded its capacity to include the manufacture of GMP synthetic psychedelics. Rather than focusing on treatment centres, therapists, clinical trials or drug development, we’ve made a strategic decision to meet the needs of the psychedelic market where they exist today. Our advantage lies in our ability to cultivate and manufacture GMP supplies of psychedelic substances that will underpin ongoing research and will be able to scale with the wider development of the industry.

You can read more about our operations here.

Thus far, Optimi Health has signed supply agreements and tentative partnerships with drug developers, psychedelic therapy educators, and clinical operators. Our goal is to further research and development and provide access through approved channels.

You can read more about our clients and partners here.

Our investment case is available here and stock information are available here.

Or enter your information to download our complete investor presentation with one click. .

SUBSCRIBE FOR NEWS AND UPDATES

Optimi Health Corp.

330 – 1122 Mainland Street, Vancouver, BC V6B 5L1

Facebook Twitter Youtube Reddit Linkedin

Investor Relations

Contact Information

E: investors@optimihealth.ca

T: +1 800 321 4555

Regulator Filings

Sedar Documents

Sedar Profile

Investor Presentation

Consultants

Legal Counsel: Norton Rose Fulbright

Auditor: Smythe CPA

Transfer Agent: Endeavor Trust

Corporate Visibility & Investor Relations: Kydder Group

Stock Information

Trading Symbol: CSE: OPTI | OTC:OPTHF |

FRA: 8BN

CUSIP Number: 68405H100

ISIN Number: CA68405H1001

WKN: A2QQEL

Issued & Outstanding: (30/06/2022) 80,451,883

Incorporated: BC / May 27, 2020

Year End: September 30th

Privacy

Disclaimer

© Copyright 2022 Optimi Health All rights reserved.
Visit OptimiLife.com

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.